Understanding the function of the tumor microenvironment, and compounds from marine organisms for breast cancer

Rama Rao Malla1, Batoul Farran2, Ganji Purnachandra Nagaraju3

  • 1Department of Biochemistry and Bioinformatics, GITAM (Deemed to be University), Visakhapatnam 530045, AP, India.

Insights

Breast cancer (BC) progression involves complex signaling pathways and immune suppression. Marine compounds offer novel therapeutic strategies targeting these pathways for improved BC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Marine Biotechnology

Background:

  • Breast cancer (BC) pathology, including metastasis and drug resistance, is driven by tumor microenvironment (TME) signaling pathways that suppress antitumor immunity.
  • Long non-coding RNAs (lncRNAs) are emerging as key mediators of BC pathophysiological developments and immune suppression within the TME.
  • The complex biology of BC necessitates novel, personalized therapeutic strategies to improve patient outcomes.

Purpose of the Study:

  • To review advances in breast neoplasia biology, encompassing cellular and molecular aspects, heterogeneity, and the TME.
  • To examine the role of novel molecules, specifically lncRNAs, in BC pathophysiology.
  • To provide an overview of anticancer compounds from marine sources and their synergistic potential in BC therapy.

Main Methods:

  • Literature review of current research on breast cancer biology, TME, lncRNAs, and marine-derived anticancer compounds.
  • Analysis of signaling pathways involved in BC progression, metastasis, and immune evasion.
  • Evaluation of the potential synergistic effects of marine compounds with existing anticancer drugs.

Main Results:

  • BC progression is significantly influenced by TME signaling and lncRNA activity, impacting antitumor immunity.
  • Marine microorganisms, crustaceans, and fishes are sources of novel compounds with diverse anticancer effects.
  • Marine compounds show promise for synergistic effects when combined with conventional therapies, targeting multiple BC pathways.

Conclusions:

  • Understanding BC's complex molecular and cellular biology, including the TME and lncRNAs, is crucial for developing effective treatments.
  • Marine-derived compounds represent a promising new avenue for BC therapy, offering unique mechanisms to target cancer progression.
  • Harnessing marine compounds could lead to innovative, synergistic therapeutic regimens to improve clinical outcomes in breast cancer patients.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
818
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.0K